Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable clinical success in the treatment of hematological malignancies. However, producing these bespoke cancer‐killing cells is a complicated ex vivo process involving leukapheresis, artificial T cell activation, and CAR construct introduction. The activation step requires the engagement of CD3/TCR and CD28 and is vital for T cell transfection and differentiation. Though antigen‐presenting cells (APCs) facilitate activation in vivo, ex vivo activation relies on antibodies against CD3 and CD28 conjugated to magnetic beads. While effective, this artificial activation adds to the complexity of CAR T cell production as the beads must be removed prior to clinical implementation. To overcome this challenge, this work develops activating lipid nanoparticles (aLNPs) that mimic APCs to combine the activation of magnetic beads and the transfection capabilities of LNPs. It is shown that aLNPs enable one‐step activation and transfection of primary human T cells with the resulting mRNA CAR T cells reducing tumor burden in a murine xenograft model, validating aLNPs as a promising platform for the rapid production of mRNA CAR T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These findings suggest that macropinocytosis is the dominant route of SM102-DD LNP internalization in primary human T cells, consistent with previous studies.34,72”
From Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles (2026) · cites this paper as [34]
In the citing paper
“EIPA (macropinocytosis inhibitor, 50 μM, MedChemExpress, Catalog Number: HY-101840)”
From Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles (2026) · cites this paper as [34]
In the citing paper
“nystatin (caveolae-mediated endocytosis inhibitor, 50 μM, Sigma-Aldrich, N4014)”
From Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles (2026) · cites this paper as [34]
In the citing paper
“Moreover, the vast design space of LNPs, including tunable lipid compositions, customizable cargo loading, and surface modifications, enables tailored solutions for a range of cell types and delivery goals.37,90,95,96”
From Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles (2026) · cites this paper as [96]
In the citing paper
“MβCD (cholesterol-dependent pathway inhibitor, 5 mM, Sigma-Aldrich, Catalog Number: C4555)”
From Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles (2026) · cites this paper as [34]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Self-citationA guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationmRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
Self-citationCAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
Self-citationCAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Self-citationLipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
CD69: from activation marker to metabolic gatekeeper
Cibrián, D., & Sánchez‐Madrid, F. (2017) · European Journal of Immunology · doi:10.1002/eji.201646837 · Cited by 948
Research works printed but not linked: 57
- FDA D. I. S. C. O. Burst Edition: FDA Approval of Breyanzi (Lisocabtagene Maraleucel) for Second‐Line Treatment of Large B‐Cell Lymphoma FDA 2022.
- FDA D. I. S. C. O. Burst Edition: FDA Approval of ABECMA (Idecabtagene Vicleucel) the First FDA Approved Cell‐Based Gene Therapy for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma FDA 2021.
- FDA D. I. S. C. O. Burst Edition: FDA Approval of CARVYKTI (Ciltacabtagene Autoleucel) for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma after Four or More Prior Lines of Therapy Including a Proteasome Inhibitor an Immunomodulatory Agent and an Anti‐CD38 Monoclonal Antibody FDA 2022.
- 10.1038/s41586-023-05707-3 · DOI · Paper page
- 10.1056/NEJMoa1610497 · DOI · Paper page
- 10.1126/scitranslmed.aaa0984 · DOI · Paper page
- 10.1038/s41419-017-0238-6 · DOI
- 10.1038/s41591-020-1039-5 · DOI · Paper page
- 10.1080/17474086.2016.1183479 · DOI
- 10.1038/mto.2016.11 · DOI · Paper page
- 10.1016/j.annonc.2020.10.478 · DOI · Paper page
- 10.1056/NEJMoa1407222 · DOI · Paper page
- 10.1038/s41586-021-04390-6 · DOI · Paper page
- 10.1016/j.jaip.2021.10.037 · DOI
- 10.1089/hum.2011.070 · DOI · Paper page
- 10.1038/gt.2015.4 · DOI
- 10.1089/hum.2018.145 · DOI · Paper page
- 10.1038/s41467-020-19486-2 · DOI · Paper page
- 10.1021/acs.nanolett.9b04246 · DOI · Paper page
- 10.1021/acs.nanolett.1c02503 · DOI · Paper page
- 10.3390/ijms21186514 · DOI · Paper page
- 10.1007/978-1-0716-0146-4_7 · DOI
- 10.1158/2326-6066.CIR-14-0051 · DOI · Paper page
- 10.1158/0008-5472.CAN-10-2880 · DOI · Paper page
- 10.1158/2326-6066.CIR-13-0170 · DOI · Paper page
- 10.1016/j.biotechadv.2021.107760 · DOI
- 10.1053/j.gastro.2018.03.029 · DOI · Paper page
- 10.1158/2326-6066.CIR-17-0189 · DOI · Paper page
- 10.1073/pnas.1809671115 · DOI · Paper page
- 10.1016/j.canlet.2019.04.040 · DOI · Paper page
- 10.1038/s41467-021-27493-0 · DOI · Paper page
- 10.1016/S0022-1759(03)00010-3 · DOI · Paper page
- 10.2217/nnm.13.98 · DOI
- 10.1016/j.nano.2013.06.015 · DOI · Paper page
- 10.1016/j.biomaterials.2013.09.050 · DOI · Paper page
- 10.1016/j.tibtech.2015.07.001 · DOI
- 10.1002/smll.201402369 · DOI · Paper page
- 10.1038/s41598-020-74595-8 · DOI
- 10.1016/j.actbio.2023.02.023 · DOI
- 10.1021/acs.nanolett.5b02497 · DOI · Paper page
- 10.1021/acsnano.5b02796 · DOI · Paper page
- 10.1016/j.ymthe.2021.06.004 · DOI · Paper page
- 10.1016/j.ymthe.2017.06.008 · DOI · Paper page
- 10.4049/jimmunol.1601494 · DOI
- 10.4049/jimmunol.161.10.5338 · DOI · Paper page
- 10.1038/s41467-019-13997-3 · DOI · Paper page
- 10.1186/s12964-021-00766-3 · DOI
- 10.1016/j.bj.2021.09.004 · DOI
- 10.1002/eji.202049055 · DOI
- 10.1097/00002371-200409000-00010 · DOI
- 10.1021/ja301621z · DOI · Paper page
- 10.1021/acs.nanolett.1c01353 · DOI · Paper page
- 10.1016/j.omtm.2018.11.010 · DOI · Paper page
- 10.1038/nnano.2014.84 · DOI · Paper page
- 10.1038/s41467-020-17029-3 · DOI · Paper page
- 10.1038/nprot.2009.22 · DOI · Paper page
- 10.1073/pnas.2218632120 · DOI
Cited by
Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles
Ramamurthy, A., Scimonelli, G., Murphy, W. L., & Saha, K. (2026) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2026.103081
Metadata
- Authors
- Metzloff, A. E., Padilla, M. S., Gong, N., Billingsley, M. M., Han, X., Merolle, M., Mai, D., Figueroa‐Espada, C. G., Thatte, A. S., Haley, R. M., Mukalel, A. J., Hamilton, A. G., Alameh, M., Weissman, D., Sheppard, N. C., June, C. H., & Mitchell, M. J.
- Affiliations
- Department of Bioengineering School of Engineering and Applied Science University of Pennsylvania Philadelphia PA 19104 USA
- Department of Pathobiology School of Veterinary Medicine University of Pennsylvania Philadelphia PA 19104 USA
- Department of Medicine University of Pennsylvania Philadelphia PA 19104 USA
- Abramson Cancer Center Perelman School of Medicine University of Pennsylvania Philadelphia PA 19104 USA
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2024-03-15
- Volume
- 36
- Issue
- 26
- ISSN
- 0935-9648
- 1521-4095
- Cited by
- 68
- References
- 16
- Language
- en
- Funders
- Emerson Collective
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy. https://app.cochat.ai/papers/10.1002/adma.202313226
- The paper
- Metzloff, A. E., Padilla, M. S., Gong, N., Billingsley, M. M., Han, X., Merolle, M., Mai, D., Figueroa‐Espada, C. G., Thatte, A. S., Haley, R. M., Mukalel, A. J., Hamilton, A. G., Alameh, M., Weissman, D., Sheppard, N. C., June, C. H., & Mitchell, M. J. (2024). Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202313226
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.